Potential drug-drug interactions in hospitalized patients with acute coronary syndrome at a tertiary care hospital in upper Egypt

埃及上部一家三级医院急性冠脉综合征住院患者潜在的药物相互作用

阅读:1

Abstract

BACKGROUND: Potential drug-drug Interactions (pDDIs) are a serious concern in cardiovascular patients and are responsible for most adverse drug reactions and drug-related hospital admissions. Clinically significant pDDIs may injure patients, create adverse outcomes, and impact healthcare costs. Therefore, pDDIs control is critical for the improvement of prescription drug safety. AIM: The present study aimed to assess potential pDDIs among cardiovascular patients at a Tertiary Care Hospital in Upper Egypt. METHODS: A prospective observational study was performed on acute coronary syndrome (ACS) patients attending Assiut University Heart Hospital. The Lexi-Interact online was used to assess pDDIs. Multiple logistic regression was used to identify the factors associated with pDDIs. RESULTS: A total of 371 patients attending Assiut University Heart Hospital were recruited for the study. A total of 2,504 pDDIs were detected among the patients. The mean number of drugs prescribed per patient was 7.78 ± 1.73. Class C, D, and X DDIs were found in 74.76%, 10.02%, and 0.04%, respectively. Aspirin and ticagrelor were the most prevalent pDDIs under category D (232, 92.4%). A combination of ramipril and aspirin was the most frequently encountered interacting pair in the class C (281, 17.2%). STEMI patients, length of hospital stay, and a higher number of prescribed drugs were significantly associated with the occurrence of pDDIs, according to multiple logistic regression. CONCLUSION: Patients with ACS were frequently exposed to pDDIs with the highest drug-related problems, treatment failure, and negative consequences. Therefore, clinical pharmacists ought to be more involved in managing complex drug regimens and improving therapeutic outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。